Hurkmans Coen, Duisters Cindy, Peters-Verhoeven Mieke, Boersma Liesbeth, Verhoeven Karolien, Bijker Nina, Crama Koen, Nuver Tonnis, van der Sangen Maurice
Department of Radiation Oncology, Catharina Hospital Eindhoven, the Netherlands.
Maastricht University Medical Centre+, Dept. of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
Tech Innov Patient Support Radiat Oncol. 2021 Jul 15;19:26-32. doi: 10.1016/j.tipsro.2021.06.004. eCollection 2021 Sep.
The aim was to reach consensus in The Netherlands on which parameters should be used to evaluate breast cancer radiotherapy (RT) plans.
A Benchmark Case with delineated planning target volumes (PTVs) and Organs At Risk (OARs) was sent to all Dutch radiotherapy centres in combination with a questionnaire, with the request to generate RT plans prescribing 15 times 2.67 Gy for four different treatment indications according to the institutional irradiation technique. The plans and accompanying questionnaire answers were analysed using descriptive statistics. These results, together with a harmonisation proposal, were sent to all centres. The proposal was discussed at a meeting of the Dutch Society of Radiation Oncology breast cancer platform. Distinct parameters were accepted if consensus on them was reached.
19 out of 20 Dutch departments participated in this study. PTV coverage varied considerably, with D98% between 63% and 99% for the breast and between 37% and 97% for the internal mammary nodes (IMN). Also substantial OAR dose differences were observed, with e.g. mean heart doses ranging between 1.85 Gy and 5.42 Gy in case the IMN were included in the PTV. For evaluation of the PTVs D98%, D2% and Dmean were chosen to report on, with target values of ≥ 95% (90% for the PTV_IMN), ≤ 107%, and 99-101%, respectively. For OARs, consensus was reached on the parameters to be evaluated, without target values: Dmean of the heart, Dmean and V5% of the lungs, and in case of periclavicular radiotherapy V30Gy of the thyroid gland. For patients younger than 40 years a contralateral mean breast dose of ≤ 1 Gy was agreed upon.
A new Dutch consensus guideline for evaluation of breast cancer RT plans has been established.
旨在就荷兰应使用哪些参数来评估乳腺癌放射治疗(RT)计划达成共识。
向荷兰所有放疗中心发送了一个带有勾画的计划靶区(PTV)和危及器官(OAR)的基准病例,并附上一份问卷,要求根据各机构的照射技术,针对四种不同的治疗指征制定规定15次、每次2.67 Gy的RT计划。使用描述性统计分析这些计划及随附的问卷答案。这些结果连同一份协调提案被发送给所有中心。该提案在荷兰放射肿瘤学会乳腺癌平台会议上进行了讨论。如果就某些特定参数达成共识,则予以接受。
20个荷兰科室中有19个参与了本研究。PTV覆盖情况差异很大,乳腺的D98%在63%至99%之间,内乳淋巴结(IMN)的D98%在37%至97%之间。还观察到OAR剂量存在显著差异,例如,若IMN包含在PTV中,平均心脏剂量在1.85 Gy至5.42 Gy之间。对于PTV评估,选择报告D98%、D2%和Dmean,其目标值分别为≥95%(PTV_IMN为90%)、≤107%和99 - 101%。对于OAR,就待评估的参数达成了共识,但未设定目标值:心脏的Dmean、肺的Dmean和V5%,以及锁骨上放疗时甲状腺的V30Gy。对于40岁以下患者,对侧平均乳腺剂量≤1 Gy达成了一致意见。
已制定了一项新的荷兰乳腺癌RT计划评估共识指南。